Home › Kanser (lahat ng uri) › Texas › Irving
Pag-aaral pangklinika para sa Kanser (lahat ng uri) sa Irving, TX
Isang pag-aaral para sa Kanser (lahat ng uri) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Irving. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- NEXT Dallas, Irving
Registry Study for Radiation Therapy Outcomes
Nagre-recruitObservasyonal na pag-aaral
- Texas Center for Proton Therapy, Irving
REC-7735 in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology - Dallas, Irving
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Nagre-recruitPhase 3
- US Oncology Research Investigational Products Center, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Dallas, Irving
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Nagre-recruitPhase 1
- NEXT Oncology ( Site 0051), Irving
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Nagre-recruitPhase 1/2
- NEXT Oncology ( Site 1012), Irving
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Nagre-recruitPhase 1/2
- NEXT Oncology Dallas, Irving
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Nagre-recruitPhase 1
- NEXT Oncology Dallas, Irving
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Dallas, Irving
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Dallas, Irving
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Nagre-recruitPhase 1
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Nagre-recruitPhase 1/2
- NEXT Dallas, Irving
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Nagre-recruitObservasyonal na pag-aaral
- Texas Center for Proton Therapy, Irving
Pag-aaral para sa Kanser (lahat ng uri) sa ibang lungsod
- Houston, TX122 pag-aaral
- New York City, NY110 pag-aaral
- Boston, MA86 pag-aaral
- Los Angeles, CA73 pag-aaral
- Nashville, TN65 pag-aaral
- Washington, DC60 pag-aaral
- Philadelphia, PA60 pag-aaral
- Durham, NC59 pag-aaral
- Chicago, IL52 pag-aaral
- Seattle, WA50 pag-aaral
- Atlanta, GA50 pag-aaral
- Arlington, VA48 pag-aaral
Iba pang pag-aaral sa Irving
- Non-Small Cell Lung Cancer22 pag-aaral
- Colorectal Cancer13 pag-aaral
- Metastatic Cancer11 pag-aaral
- Kanser sa Pancreas7 pag-aaral
- Kanser sa Tiyan7 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg6 pag-aaral
- Kanser sa Baga6 pag-aaral
- Small Cell Lung Cancer6 pag-aaral
- Kanser sa Suso6 pag-aaral
- Kanser sa Ovary5 pag-aaral
- Triple-Negative Breast Cancer4 pag-aaral
- Kanser sa Esophagus4 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.